Branched-linear and agglomerate protein polymers as vaccine platforms

scientific article

Branched-linear and agglomerate protein polymers as vaccine platforms is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BIOMATERIALS.2014.06.021
P932PMC publication ID4137571
P698PubMed publication ID24985736
P5875ResearchGate publication ID263704658

P50authorLeyi WangQ42411029
Dianjun CaoQ58428833
Xiang-Jin MengQ88025910
Ming TanQ115232766
P2093author name stringMing Xia
Pengwei Huang
Xi Jiang
Hao Fang
Monica McNeal
P2860cites workEfficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialQ45189946
Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine developmentQ45358131
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialQ45552005
Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometryQ46851930
Human hepatitis B vaccine from recombinant yeastQ52850114
Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans.Q54294858
E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability.Q54497752
Porcine circovirus type 2 (PCV2) viral components immunomodulate recall antigen responsesQ57207435
Amgen swallows Micromet to BiTE into ALL marketQ83852281
The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptorsQ24563224
Structural basis for the recognition of blood group trisaccharides by norovirusQ24682901
X-ray structure of glutathione S -transferase from the malarial parasite Plasmodium falciparumQ27642569
Structural Basis for the Receptor Binding Specificity of Norwalk VirusQ27650214
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virusQ27651029
Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host InteractionQ27656916
Crystal structure of the human astrovirus capsid spikeQ27670881
Crystallography of a Lewis-Binding Norovirus, Elucidation of Strain-Specificity to the Polymorphic Human Histo-Blood Group AntigensQ27671411
Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.Q32180102
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patternsQ33788719
Subviral particle as vaccine and vaccine platformQ33812653
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infectionQ34054427
The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptorsQ34123964
Serological Correlate of Protection against Norovirus‐Induced GastroenteritisQ34153875
Molecular virology of hepatitis E virusQ34166393
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialQ34415030
Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody ProductionQ34485266
Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particlesQ34724844
C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein.Q35023707
A candidate dual vaccine against influenza and norovirusesQ35301295
Serological evidence for a hepatitis e virus-related agent in goats in the United StatesQ36420009
Noroviral P particle: structure, function and applications in virus-host interactionQ36429481
Polyvalent complexes for vaccine developmentQ36792270
Norovirus vaccine against experimental human Norwalk Virus illnessQ37144052
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenicQ37353496
A dual vaccine candidate against norovirus and hepatitis E virusQ37502688
Viral nanoparticles and virus-like particles: platforms for contemporary vaccine designQ37792984
Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patternsQ38353300
Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccineQ39681193
Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assayQ40316613
P433issue29
P304page(s)8427-8438
P577publication date2014-06-28
P1433published inBiomaterialsQ15751139
P1476titleBranched-linear and agglomerate protein polymers as vaccine platforms
P478volume35

Reverse relations

cites work (P2860)
Q36519453A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus
Q35152899Affinities of human histo-blood group antigens for norovirus capsid protein complexes
Q91576751Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform
Q47547891Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model.
Q36914794Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
Q104289416Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine
Q34160482Gangliosides are ligands for human noroviruses
Q30234848Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy
Q92759295Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice
Q90231715Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development
Q36275589Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives
Q38819439Recent advancements in combination subunit vaccine development
Q57154565Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection

Search more.